VistaGen Therapeutics
VTGN
85 hedge funds and large institutions have $4.75M invested in VistaGen Therapeutics in 2022 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 23 increasing their positions, 25 reducing their positions, and 17 closing their positions.
100% more call options, than puts
Call options by funds: $4K | Put options by funds: $2K
0.25% less ownership
Funds ownership: 0.91% → 0.66% (-0.25%)
8% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 25
8% less funds holding
Funds holding: 92 → 85 (-7)
41% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 17
48% less capital invested
Capital invested by funds: $9.13M → $4.75M (-$4.39M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$71.9K |
| 2 |
State Street
Boston,
Massachusetts
|
+$66.6K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$30.9K |
| 4 |
GWSG
GPS Wealth Strategies Group
Centennial,
Colorado
|
+$30.9K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$22.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$1.38M |
| 2 |
Renaissance Technologies
New York
|
-$459K |
| 3 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$155K |
| 4 |
Millennium Management
New York
|
-$93.7K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$52.4K |
VTGN Hedge Fund Activity: Q4 2022 in Review
85 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q4 2022, worth a combined $4.75M — down 48% from $9.13M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of VTGN and 10 opened new positions — a net loss of 7 holders — while 25 trimmed existing stakes and 23 added.
The largest buyer was BlackRock, adding an estimated $71.9K. The largest seller was Franklin Resources, exiting entirely with an estimated $1.38M sold.
- 85 institutional investors held VistaGen Therapeutics (VTGN) as of Q4 2022, down from 92 in Q3 2022.
- Funds reported $4.75M of VistaGen Therapeutics stock for Q4 2022, down 48% quarter-over-quarter.
- 10 funds opened new VistaGen Therapeutics positions in Q4 2022 and 17 closed out, a net change of -7 holders.
- The largest VistaGen Therapeutics buyer in Q4 2022 was BlackRock, an estimated $71.9K added.
- The largest VistaGen Therapeutics seller in Q4 2022 was Franklin Resources, an estimated $1.38M sold.
Based on aggregated 13F filings for Q4 2022.